NewsEvents

Your Yourlocation: Home > Tiotropium bromide(136310-93-5) better to prevent acute exacerbation of lung function

COPD is associated with persistent airflow obstruction and it is reasonable to expect a better control of COPD within 24 hours. Tiotropium bromide(136310-93-5) was the first inhaled bronchodilator to do this, compared with twice daily beta-long-acting agonist (LABA), which improved the mean forced expiratory volume (FEV1) at 1 second And valley.

Indaclitaxel is the first daily LABA drug that improves FEV1 troughs significantly compared with placebo, formoterol, or flumexazole plus salmeterol / fluticasone propionate.

Many of these initial indacaterol studies recruited less severe COPD patients and the end point was shown to be improved compared with placebo, such as dyspnea.

Donohue et al. Found that, after 26 weeks of treatment, at least in the improvement of lung function and reduce dyspnea in tiotropium bromide(136310-93-5) at least. In the INVIGORATE study, which included 3444 patients, patients were randomized to indacaterol or tiotropium and were followed for 1 year. This non-inferiority study has shown that both drugs are inferior in improving lung function, but tiotropium bromide(136310-93-5) is better at preventing acute exacerbations. Therefore, studies have shown that LAMA is superior to LABA in the prevention of COPD acute exacerbations of the cause is still unclear.

The other two once-daily LABAs have been registered, Odatro and Vilantro. In each case, reports of these registry studies show that, like indacaterol, these drugs are rapidly active, lasting for 24 hours without rapid tolerance. So far, there is no direct comparison between these drugs.

Two new LAMAs are also available, although glycopyrrolate is available in two different formulations. But this drug and bralibromide are similar in improving lung function and other structures. The SPARK study showed that glycopyrrolate was similar in frequency to tiotropium bromide(136310-93-5), although moderate and severe events were less frequent in tiotropium bromide(136310-93-5).

Daily Inhaled Corticosteroids (ICS) Fluticasone furoate (FF) has been used to treat COPD and asthma. In addition, FF improved FEV1 for more than 24 hours compared with placebo. And repetitive administration has a sustained effect. ICS monotherapy has not been approved for the treatment of chronic obstructive pulmonary disease, FF is only recommended in conjunction with LABA Vilantro.

Finally, two long-acting inhaled bronchodilators have been shown to provide 24-hour bronchodilatation. Acetylbromide was originally administered once a day, but the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) considered it twice a day more appropriate. Comparison of effects on acute exacerbation of COPD There was no difference between 400 μg once daily and 200 μg twice daily, but the latter is currently a registered dose, and a future dosage form, when used in combination with formoterol dosing regimen.

Address:211#Zhengfeng Building,Huanbaokejiyuan, Gaoxinkaifaqu, Jinan,250100,China TEL:086-531-82375818 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved